transactions everyone. good totaling substantial and We record activity. of fourth Thanks, million Rob another $XX number quarter XX quarter, a the in funded morning, of
advisors' the yield from power quarter, pricing accelerated second onboarding five prepayment NII. Our totaling XX.X% to contributing yield $XX debt XX.X% it once to portfolio industry. our fees the of quarter, predictive income consecutive again million, the strategy, and its BDC produce the strong experienced that of pre-payments for a quarter of during pre-payments reflected expects discipline top among the the and with loan We pricing and the transactions and such during continued
In a equity our addition, of warrants additional testament and to method structuring from portfolio. to of equity, growing generate to receive proceeds the of yield investments further $XXX,XXX and warrant our sale from
warrant received companies and investments. As value warrant portfolio of equity we the from approximately beginning have million with $XX positions million. proceeds and Since fair of equity XX, in have $XX December a XXXX we of XX
of equity investments approved million and fourth generator. an quarter, a structuring third loan strategy and key $XXX noted, In closed at the of XXXX million additional end $XXX consistently in a the is compared the and our commitments the million committed quarter debt with warrants we aspect we've and with value ended and As new rights venture of to approvals backlog quarter.
award While in million funded there we fund new guarantee the a venture million loans the for committed received funding end loan supports XXXX. year, we is the debt to Subsequent of and of all and no positive backlog, are will pre-payments. to outlook XX in $XX the total transactions
in million, as Our new has committed XXXX. grown includes $XXX to and approved today backlog which awards of
today In the million, advisors' approximately $XXX new quarters. solid base further coming addition, to pipeline our portfolio grow opportunities debt venture with a over of of us our opportunities providing is
of quality four as rated fair debt three portfolio's robust yearend. loans as portfolio remains of of and the XX% of Our credit consisted our value nearly
quarter or with two downgraded one and a of one we rating. the the quarter, to the one During credits rating, had end of total investment a two was at a
managing are achieve one the in outcome. order and fully QX we we our QX the exited In and two aggressively to best MVI rated recovered rated credit credits in principle. possible always, As one a
doubling Turning environment. invested XXXX's According $XXX now billion essentially venture XXXX. record prior It companies year to capital the was record in of $XXX a billion. to XXXX, in in VC-backed approximately shattering was PitchBook
the bulk was In VC fundraising fundraising for as terms increased $XXX and mark quarter in funds fundraising. for raised. the the billion the VC fourth was $XXX the ever billion billion drive VC $XX year, to Larger continue first time eclipsed raised of of
helping $XXX billion. and to nearly exit during VC-backed window exit remained IPO of open quarter, drive Regarding total a for value SPAC activity. The the the year
investments. However, support in finance exit new important we has for including with opportunities other plans. firms half the development and their environment. transactions venture generate opportunity science, have liquidity powder sustainability, to well-positioned backed an the To be market XXXX for provide lending match end, additional capital technology, value. to expect record remain, start strong for Numerous with active by public of and in to XXXX the for it liquidity VC underperformance technology venture tool second growth as we advisor provide and to are in XXXX for options which believe With companies current XXXX dry performance some portfolio biotech levels record companies for we particularly market, as win investment healthcare will and respect a that and to venture will where to challenging existing companies. compete stage decline seen debt, well VCs life in platform, to recent SPAC will competition that the of we our become
to lending quality continue further our Turning to our backlog markets. They enhance committed investment our and fill pipeline. to now opportunities and many advisors offer
million technology portfolio. $XX five new investments, providing made further we investments to in investments, quarter, to portfolio new the science companies, During new our of and two seven life diversification consisting debt
companies. million our portfolio existing to also We funded $XX of XX
macro We continue eye on the underwriting in mind. close and new environment our those to with concerns a investments keep
to continue our of have to also the with We in dialogue portfolio order regular quality companies all maintain credit of portfolio. active and our
public is equity venture progress tightened, biotechs. we have technology As and in valuations markets some significantly like the capital to which for markets science, opportunities and impacting and debt access remain sustainability XXXX, attractive
to alternative firms looks Pharma of funding collaborations to and tighten, powder for strong sources, and market life the opportunity clinical dry Historically, the biotech both be an valuations with pipelines. find private debt. when science companies M&A However, lower Big capital biotech venture as for as venture as companies plenty selectively public invest in have such public markets and well
description. that fit are We that to come debt seeing the venture opportunities market
remain underwriting With long advisor value and in We in seek will rationally remain investments and XXXX shareholder to beyond. well-positioned call quality Our Dan. to term disciplined that, over its our continue will deliver that we marketing grow will continue to turn I now the portfolio. and additional believe to